UFP Technologies, Inc.
UFPT Healthcare Medical Devices
UFP Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $602.8 million, up 19.5% from fiscal 2024.
- Revenue
- +11.6%
- EPS
- +25.6%
- Free cash flow
- −35.8%
- Total debt
- −40.2%
Quarter to September 2026, against a year earlier
Follow UFPT
Alert me
UFP Technologies, Inc. (UFPT) P/B ratio
As of 5 November 2026, UFP Technologies, Inc. (UFPT) trades at a P/B ratio of 5.0×. Over the past ten years it has ranged from 1.4× (July 2015) to 8.9× (September 2024); the current reading is higher than 87% of that period. That is above the Medical Devices industry median of 2.5× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 4.0× | (26.22%) |
| FY2024 | 5.5× | 23.76% |
| FY2023 | 4.4× | 20.09% |
| FY2022 | 3.7× | 35.37% |
| FY2021 | 2.7× | 37.89% |
| FY2020 | 2.0× | (13.28%) |
| FY2019 | 2.3× | 44.70% |
| FY2018 | 1.6× | (2.65%) |
| FY2017 | 1.6× | (1.44%) |
| FY2016 | 1.6× | 0.26% |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 5.0× | 12.04% |
| Jun 2026 | 4.4× | 30.29% |
| Mar 2026 | 3.4× | (15.61%) |
| Dec 2025 | 4.0× | 5.90% |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| NEOG Neogen Corporation compare | 1.2× |
| INSP Inspire Medical Systems, Inc. compare | 2.3× |
| TMDX TransMedics Group, Inc. compare | 4.3× |
| NVCR NovoCure Limited compare | 4.5× |
| UFPT UFP Technologies, Inc. | 5.0× |
| AXGN AxoGen, Inc. compare | 5.4× |
| ALMR Alamar Biosciences, Inc. compare | 6.2× |
| BFLY Butterfly Network, Inc. compare | 8.8× |
| ESTA Establishment Labs Holdings Inc. compare | 89.6× |
| Medical Devices industry median | 2.5× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on UFPT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement